参考文献/References:
[1].Antithrombotic Trialists’ (ATT) Collaboration,?Baigent C,?Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials[J]Lancet,2009,373(9678):1849-1860.
[2].McNeil JJ, Wolfe R, Woods RL, et al. Effect of?aspirin?on cardiovascular events and bleeding in the healthy?elderly[J]. N Engl J Med,2018,379(16):1509-1518.
[3].Arnett DK,Blumenthal RS,Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease[J]. J Am Coll Cardiol,2019,74(10):1376-1414.
[4].Patrono C, Baigent C. Role of aspirin in primary prevention of cardiovascular disease [J]. Nat Rev Cardiol,2019,16(11):675-686.
[5]. Piccolo R,?Magnani G,?Ariotti S, et al. Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention:insights from the PRODIGY randomised trial [J]. EuroIntervention,2017,13(1):78-86.
[6]. Valgimigli M,Bueno H,Byrne RA,et al. 2017 ESC focused?update?on?dual?antiplatelet?therapy?in?coronary artery disease?developed?in?collaboration?with?EACTS: The Task Force for?dual?antiplatelet?therapy?in?coronary artery disease?of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)[J]. Eur Heart J,2018, 39(3):213-260.
[7].Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med,2007,357(20):2001-2015.
[8].Wallentin L,?James S,?Ekman I, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes [J]. N Engl J Med,2009,361(11):1045-1057.
[9].中国医师协会心血管内科医师分会血栓防治专业委员会. 替格瑞洛临床应用中国专家共识[J].中华心血管病杂志,2016,44(2):112-120.
[10].海峡两岸医药卫生交流协会老年医学专业委员会.75岁以上老年抗栓治疗专家共识[J].中国心血管杂志,2017,22(3):161-168.
[11].[11] 李志华,张亚臣,解玉泉,等.替格瑞洛在行经皮冠状动脉介入治疗的急性冠状动脉综合征患者中的疗效和安全性观察[J].中国介入心脏病学杂志,2015,23(8):45-49.
[12].Eikelboom JW,Connolly SJ,Bosch J,et al. Rivaroxaban with or without aspirin in stable cardiovascular disease[J]. N Engl J Med,2017,377(14):1319-1330.
[13].Morrow DA,Braunwald E,Bonaca MP,et al. Vorapaxar in the secondary prevention of atherothrombotic events[J]. N Engl J Med,2012,366(15):1404-1413.
[14].Bonaca MP,Bhatt DL,Cohen M,et al. Long-term use of ticagrelor in patients with prior myocardial infarction[J]. N Engl J Med,2015,372(19):1791-800.
[15]. Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI [J]. N Engl J Med,2016,375(25):2423-2434.
[16]. Cannon CP,Bhatt DL,Oldgren J,et al.Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation[J]. N Engl J Med,2017,377(16):1513-1524.
[17]. Li L,?Geraghty OC,?Mehta Z,et al. Age-specific?risks,severity,time?course,and outcome of bleeding on long-term antiplatelet treatment after?vascular?events: a?population-based?cohort?study[J]. Lancet,2017,390(10093):490-499.
[18]. Fischbach W,Malfertheiner P,Jansen PL,et al. S2k-Guideline Helicobacter pylori and gastroduodenal ulcer disease[J]. Z Gastroenterol,2017,55(2):167-206. 收稿日期：2019-10-27
相似文献/References:
[1]周召锋,吴春阳.急性冠状动脉综合征的抗血小板治疗进展[J].心血管病学进展,2015,(5):646.[doi:10.3969/j.issn.1004-3934.2015.05.032]
ZHOU Zhaofeng,WU Chunyang.Development of Antiplatelet Therapy for Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2015,(8):646.[doi:10.3969/j.issn.1004-3934.2015.05.032]
[2]朱志伦 田乃亮.急性冠脉综合征患者抗血小板降阶治疗方案研究进展[J].心血管病学进展,2021,(6):534.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.014]
ZHU Zhilun,TIAN Nailiang.Advances in De-Escalation of Anti-Platelet Therapy in Patients with Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2021,(8):534.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.014]
[3]王亚辉 杨滨.血液透析对行经皮冠状动脉介入治疗的患者合用阿司匹林及氯吡格雷抗血小板聚集的影响[J].心血管病学进展,2021,(10):946.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.020]
WANG YahuiYANG Bin.Effect of Hemodialysis on the Antiplatelet Aggregation of Patients Undergoing Percutaneous Coronary Intervention Combined with Aspirin and Clopidogrel[J].Advances in Cardiovascular Diseases,2021,(8):946.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.020]
[4]陈纪元 陆泓雨 贺子熠 韩江莉.冠心病合并慢性肾脏病患者P2Y12受体拮抗剂治疗进展[J].心血管病学进展,2022,(7):582.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
CHEN Jiyuan,LU Hongyu,HE Ziyi,et al.P2Y12 Antagonists for Patients with Chronic Kidney Diseases and Coronary Heart Diseases[J].Advances in Cardiovascular Diseases,2022,(8):582.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[5]徐蓉玮 王亚玲.冠状动脉非阻塞性心肌梗死抗血小板治疗作用[J].心血管病学进展,2022,(10):888.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.006]
XU RongweiWANG Yaling.Role of Antiplatelet Therapy in Myocardial Infarction with Non-obstructive Coronary Arteries[J].Advances in Cardiovascular Diseases,2022,(8):888.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.006]
[6]刘娟 熊诗强 蔡琳.经皮冠状动脉介入治疗术后出血风险评估研究进展[J].心血管病学进展,2023,(4):303.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.004]
LIU Juan,XIONG Shiqiang,CAI Lin.Bleeding Risk Assessment After Percutaneous Coronary Intervention[J].Advances in Cardiovascular Diseases,2023,(8):303.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.004]
[7]吕易非 李紫凡 邵褀睿 韩江莉.急性冠脉综合征合并高出血风险患者双联抗血小板治疗研究进展[J].心血管病学进展,2023,(7):577.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.001]
LV Yifei,LI Zifan,SHAO Qirui,et al.Dual Antiplatelet Therapy for Patients with Acute Coronary Syndrome and High Bleeding Risk[J].Advances in Cardiovascular Diseases,2023,(8):577.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.001]
[8]努尔古丽·玉苏普 古力尼尕尔·麦麦提吐尔孙 陈清杰 艾尔肯·阿吉.急性冠脉综合征合并糖尿病患者P2Y12受体拮抗剂治疗进展[J].心血管病学进展,2023,(7):593.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.005]
Nurgul·Yusup,Gulinigar·Mamattursun,CHEN Qingjie,et al.P2Y12 Receptor Antagonist Therapy in A cute Coronary Syndrome with Diabetes[J].Advances in Cardiovascular Diseases,2023,(8):593.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.005]
[9]崔鸿杰 吴英锋.CYP2C19基因多态性指导抗血小板治疗的研究现状[J].心血管病学进展,2023,(11):1019.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.014]
Cui Hongjie,Wu Yingfeng.CYP2C19 gene polymorphism for antiplatelet therapy[J].Advances in Cardiovascular Diseases,2023,(8):1019.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.014]